Evommune, Inc. IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Evommune, Inc. | EVMN - NYSE |
$15.00-$17.00 |
$16.00 |
$17.25 | 9.375 million | 11/6/2025 |
| Morgan Stanley, Leerink Partners, Evercore ISI, Cantor
|
Co-Manager(s): |
| Health Care |
Filing(s):
Filed 2025-10-09
Terms Added 2025-10-17
|
For IPO Boutique's "scale of 1 to 5" BUY rating on Evommune, Inc., and our comprehensive analysis, click "Buy Market Research".
Evommune, Inc. Quote & Chart - Click for current quote -
EVMN
About Evommune, Inc. (adapted from Evommune, Inc. prospectus):
Evommune is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. Its lead programs include EVO756, an oral antagonist targeting MRGPRX2, and EVO301, a fusion biologic targeting IL-18.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "EVMN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2026 IPO Boutique. All Rights Reserved
